Sugi Predict

Sugi Predict / Compounds / SCHEMBL1760077

SCHEMBL1760077

SCHEMBL1760077

NC(=O)c1ccnc(Cl)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CASP1 P29466 3/20 0.41
▸ NNMT P40261 2/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ ATR Q13535 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ SIRT3 Q9NTG7 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741249 1.00 KDM4E (0.43) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL6959623 0.83 SMN1; SMN2 (0.45) KDM4EL3MBTL1SMN1; SMN2LMNARAB9A
SCHEMBL22866882 0.82 CASP1 (0.42) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL17793701 0.82 KDM4E (0.46) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL15645010 0.82 KDM4E (0.42) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL29439687 0.82 KDM4E (0.42) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL16181393 0.82 KDM4E (0.46) KDM4EL3MBTL1SMN1; SMN2CASP1NNMT
SCHEMBL83616 0.81 SMN1; SMN2 (0.59) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL29486104 0.81 SMN1; SMN2 (0.59) KDM4EL3MBTL1SMN1; SMN2LMNACASP1
SCHEMBL1031057 0.81 SMN1; SMN2 (0.44) KDM4EL3MBTL1SMN1; SMN2LMNAATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2854532-A1 COMPOSITIONS COMPRISING A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE Bayer Cropscience AG (DE) 2015-04-08 — — EP claimed
WO-2013178663-A1 COMPOSITIONS COMPRISING A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE BAYER CROPSCIENCE AG (DE) 2013-12-05 — — WO claimed
US-12534456-B2 Heterocyclyl pyridines as novel fungicides BAYER AKTIENGESELLSCHAFT (DE) 2026-01-27 — — US disclosed
US-12329799-B2 Peptidyl inhibitors of calcineurin-NFAT interaction OHIO STATE INNOVATION FOUNDATION (US) 2025-06-17 — — US disclosed
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION 2024-02-01 — — US disclosed
US-20230295138-A1 HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-21 — — US disclosed
US-11576946-B2 Peptidyl inhibitors of calcineurin-NFAT interaction OHIO STATE INNOVATION FOUNDATION (US) 2023-02-14 — — US disclosed
EP-3999493-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2022-05-25 — — EP disclosed
US-20210169966-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION 2021-06-10 — — US disclosed
EP-3749365-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION Ohio State Innovation Foundation (US) 2020-12-16 — — EP disclosed
WO-2019148194-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 — — WO disclosed
WO-2011057973-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 — — WO disclosed
WO-2010025416-A1 CXCR4 ANTAGONISTS FOR KIDNEY INJURY GENZYME CORPORATION (US) 2010-03-04 — — WO disclosed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 — — EP disclosed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 — — WO disclosed
CN-1237061-C Chemokine receptor binding heterocyclic compounds ANORMED INC (CA) 2006-01-18 — — CN disclosed
CN-1458929-A Chemokine receptor binding heterocyclic compounds ANORMED INC (CA) 2003-11-26 — — CN disclosed
EP-1317443-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 — — EP disclosed
WO-2002022599-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 — — WO disclosed
CN-86106552-A N-benzenesulfonyl Isonicotinamide derivative and they purposes as mycocide and sterilant — 1987-05-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295138-A1 HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES PNPO, CBR3, HPD KDM4E 413/4885L3MBTL1 3498/4885SMN1; SMN2 4583/4885
US-20210169966-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION CHP1, NFATC1, PPP3R1 KDM4E 876/4885L3MBTL1 1282/4885SMN1; SMN2 4834/4885
US-12329799-B2 Peptidyl inhibitors of calcineurin-NFAT interaction CHP1, NFATC1, PPP3R1 KDM4E 902/4885L3MBTL1 1259/4885SMN1; SMN2 4834/4885
US-12534456-B2 Heterocyclyl pyridines as novel fungicides CBR1, CBR3, NOX1 KDM4E 1655/4885L3MBTL1 1316/4885SMN1; SMN2 3816/4885
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION CHP1, NFATC1, PPP3R1 KDM4E 902/4885L3MBTL1 1259/4885SMN1; SMN2 4834/4885
US-11576946-B2 Peptidyl inhibitors of calcineurin-NFAT interaction CHP1, NFATC1, PPP3R1 KDM4E 902/4885L3MBTL1 1259/4885SMN1; SMN2 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.